Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria's (MO) fourth-quarter 2020 results are likely to reflect gains from pricing as well as strength in the Oral Tobacco Products segment, though cigarette volumes have been soft for a while.

Factors to Know Ahead of Altria's (MO) Q4 Earnings Release

Altria (MO) closed at $41.83 in the latest trading session, marking a -0.26% move from the prior day.

Altria (MO) Stock Moves -0.26%: What You Should Know

Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Altria (MO) Beat Estimates Again in Its Next Earnings Report?

Altria's (MO) efforts to boost oral tobacco offerings and expansion of IQOS across stores are yielding. Moreover, pricing power is aiding revenue growth.

Altria (MO) Gains on Low Risk Tobacco Products & Strong Pricing

Anheuser-Busch InBev

The tobacco conglomerate owns 10% of the beer company.

Should Altria Group Sell Its Stake in Anheuser Busch?

We believe Altria stock may be a decent opportunity at the moment. MO trades at $41 currently and is in fact down 18% from $50 at the beginning of 2020.

Can Altria Stock Surpass Its Pre-Covid Level?

International Flavors & Fragrances

Leggett & Platt

Lowe's

Philip Morris

Pinnacle West Capital

AT&T

Tyson Foods

Verizon

Whirlpool

The time has come for us to look at just what sort of companies may be appealing to invest in during January of 2021. We look at the areas of Basic Materials/Chemicals, Communications as well as Consumer Goods, both staples and discretionary companies.

January 2021 Undervaluation - Materials, Communications, And Consumer Goods

Altria has a wide economic moat around its business, but the company is faced with a trend of declining smokers, that is lasting for decades already. With a dividend yield of 8% the stock seems interesting for dividend investors.

Altria: Reasons To Buy And Reasons To Avoid

Altria is a regulatory capture play that sells addictive products. Its stock has recently performed poorly due to poor acquisition timing, regulatory worries, and changing sentiment.

Altria Is The Anti-Tesla

Bank of Montreal

Bank of Nova Scotia

ConocoPhillips

MicroSectors Gold Miners 3X Inverse Leveraged ETN

MicroSectors Gold Miners 3X Leveraged ETN

Phillips 66

Exxon Mobil

Canadian banks are hated and cheap. I'm buying. Tobacco is historically the most profitable industry for shareholders over the long run.

3 Value Investing Ideas For 2021

American States Water

Clorox

Chevron

DTE Energy

Enbridge

Home Depot

Johnson & Johnson

Moderna

Pfizer

Visa

Energy Select Sector SPDR Fund

Year 2020 was wild, and left many important threats for 2021. I will summarize the key threats I see, and offer my approach to the markets.

A Dividend Investor's Guide To 2021: The Cure To Uncertain Times

RICHMOND, Va.--(BUSINESS WIRE)---- $MO--ALTRIA TO HOST WEBCAST OF 2020 FOURTH-QUARTER AND FULL-YEAR RESULTS

Altria to Host Webcast of 2020 Fourth-Quarter and Full-Year Results

Aphria

Green Thumb Industries Inc.

GW Pharmaceuticals

Trulieve Cannabis Corp.

Curaleaf Holdings, Inc.

Many marijuana stocks show promise in 2021, but these specific stocks have the best shot to build upon their strong performances last year. The post The Top 7 Marijuana Stocks to Buy for January appeared first on InvestorPlace.

The Top 7 Marijuana Stocks to Buy for January

The tobacco industry is better off than people realize.

Why Altria Group Has Such a Safe Dividend

Stimulus euphoria has driven the market to all-time highs and the S&P 500 is 38% historically overvalued. But safe blue-chips, at safe prices, are still available if you know where to look.

6 Reasons 8.3% Yielding Altria Is The Best Dividend Aristocrat You Can Buy For 2021

AstraZeneca

Duke Energy

Intel

Lockheed Martin

Molson Coors Brewing

With growth names still flying high, value stocks to buy doesn't exactly inspire excitement. Nevertheless, it could be the most prudent choice ahead of an uncertain 2021.

8 Value Stocks That Could Perform Surprisingly Well In 2021

The tobacco giant's competitive advantages have bolstered it for more than 100 years, despite regulatory pressure.

3 Ways a Massive Moat Helps Altria Thrive

MO faces significant growth challenges as demonstrated by its poor Q1 results. That being said, there is a strong case to be made that its lengthy track record of excellence will continue.

Why We Are Staying Out Of Altria

Apple

Netflix

Tesla

2020 was a year to remember and not in a good way. I might be setting myself up for some interesting comments with this very short but direct article.

Retirement Strategy: Start 2021 Off With These Hated Dividend Aristocrats And Kings To Jump-Start Your Income Stream

Not even favorable market conditions seemed to help the tobacco giant.

Why Altria's Stock Fell 16.8% in 2020

Altria has had a difficult year, however, despite that, the company remains a great investment for the 2020s. The company has strong earnings potential, and its earnings should continue going forward. This supports its dividend of more than 8%, which should continue.

Altria Remains A Great Investment For The 2020s

Annaly Capital

With yields ranging from 7.3% to 10.4%, these companies are an income investors' dream come true.

3 Ultra-High-Yield Dividend Stocks to Buy With Your $600 Stimulus Check

Biogen

Bank of New York Mellon

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Merck

Roche Holding AG

Sanofi

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The January 2021 Heat Map

News for Altria Stock (MO)